Trial Profile
Phase II, Single-arm Study of Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations(SUKSES-B)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms SUKSES-B
- 16 Oct 2023 Results published in the Cancer.
- 08 Jun 2021 Results evaluating clinical efficacy of olaparib monotherapy or combination with ceralasertib presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 16 Feb 2021 Status changed from recruiting to completed.